Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”
Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”
Lea Gerischer, Andreas Meisel, Jutta Schroeder-Braunstein, Guido Wabnitz
Journal
Annals of Clinical and Translational Neurology
Topics
Complement system in diseases
article
Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”
Lea Gerischer, Andreas Meisel, Jutta Schroeder-Braunstein, Guido Wabnitz
article en
Abstract
No abstract available for this paper.
Publication Tag
Annals of Clinical and Translational Neurology
Institutions
Heidelberg University (DE), University Hospital Heidelberg (DE), Humboldt-Universität zu Berlin (DE), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), Charité - Universitätsmedizin Berlin (DE)